Our findings suggest that miR-29a inhibition via specific miR-29a inhibitors in highly metastatic cells reduces the metastatic phenotypes as well as elevating TET family members and SOCS1 expression provide a solid rationale for therapeutic miR-29a targeting to prevent HCC metastatic phenotypes. This evidence concerns the gene SOCS1 and hepatocellular carcinoma.